Closing the Annual Conference 2023, we would like to thank all our stakeholders for their engagement and support for our shared mission to improve effective cancer treatment and empower patients.
For those interested in our discussion during the last session, “Optimization of Treatment-Dose and Schedule”, here are our take-home messages:
♦ MTD is no longer the holy grail in early studies
♦ Initial randomized optimization studies can be underpowered
♦ Dose discontinuation should be an ultimate part of dose optimization studies